← All trials
NCT06330038
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 1, 2024
- Primary completion
- Dec 31, 2028
- Completion date
- Dec 31, 2028
- First posted
- Mar 26, 2024
- Last posted
- Mar 28, 2024
- Enrollment
- 5384
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Sungkyunkwan UniversityLead sponsor
- University of VirginiaCollaborator
- Inha UniversityCollaborator
- Peking UniversityCollaborator
- Mayo ClinicCollaborator
- Seoul National UniversityCollaborator
- University of WarwickCollaborator
- Chungnam National UniversityCollaborator
- Catholic University of KoreaCollaborator
- Yale UniversityCollaborator
- Qingdao UniversityCollaborator
- Ewha Womans UniversityCollaborator
- KhonKaen UniversityCollaborator
- Sungkyunkwan UniversityOfficial
- Chulalongkorn UniversityCollaborator
- All India Institute of Medical SciencesCollaborator
- University of UlsanCollaborator
- Dongguk UniversityCollaborator
- Konkuk UniversityCollaborator
- Korea UniversityCollaborator
- Memorial Sloan-Kettering Cancer CenterCollaborator
- Sungkyunkwan UniversitySponsor investigator
- Yonsei UniversityCollaborator
- The University of Texas, DallasCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.